Pacritinib (5), an inhibitor of both wild-type and mutant (V617F) JAK2 as well as FMS-like tyrosine kinase 3 (FLT3), is employed in the treatment of primary and secondary myelofibrosis (MF) in adult patients with significantly weakened platelet counts. Here, FLT3 is linked to myelofibrosis.